Branch Retinal Vein Occlusion: Symptoms, Causes & Treatment

Branch retinal vein occlusion (BRVO) is a blockage in one of the smaller veins that drain blood from the retina, almost always occurring at a spot where a retinal artery crosses over and physically compresses the vein beneath it. It typically causes sudden, painless vision loss or blurring in part of one eye, and it ranks among the most common retinal vascular disorders after diabetic eye disease. The condition is tightly linked to high blood pressure and other cardiovascular risk factors, and the main treatments now center on injections that target a growth factor driving swelling in the retina.

What Happens at the Arteriovenous Crossing

Inside the retina, arteries and veins share a tight connective-tissue sheath wherever they cross each other. In a healthy eye this is harmless. But when the artery stiffens from atherosclerosis or chronic high blood pressure, it can squeeze the softer vein beneath it, narrowing the vein’s channel and slowing blood flow. Over time the turbulence and compression damage the inner wall of the vein, making it prone to clotting. That combination of mechanical compression, vessel-wall damage, and changes in blood-clotting factors is the core recipe for BRVO.¹

The physical arrangement matters more than you might expect. Research has shown that when arteriovenous crossings are spaced closely together, the cumulative mechanical pressure on the vein increases, raising the likelihood of occlusion. Loss of arterial elasticity worsens the effect because a stiff artery contracts the shared outer sheath, further pinching the vein. The internal limiting membrane of the retina also contributes by pressing the vein against the artery from the other side, essentially sandwiching it.²

Symptoms and How BRVO Feels

Most people notice a sudden, painless decrease in vision in one eye. Because only a branch of the vein is blocked rather than the main trunk, the visual disturbance usually affects just a portion of the visual field, often the upper or lower half. Some people describe it as a blurry or dark patch that appeared over hours or overnight. Straight lines may look wavy if swelling develops in the macula, the central part of the retina responsible for sharp, detailed sight.

In milder cases, especially when the blockage occurs far from the macula, people can have BRVO and barely notice. These cases sometimes show up incidentally during a routine dilated eye exam. The severity of symptoms depends largely on two things: how close the blockage is to the center of the retina and whether fluid starts leaking into the macula.

Who Gets BRVO

High blood pressure is the single biggest systemic risk factor. A large population study found that hypertension was associated with more than a fivefold increase in the odds of having BRVO, and that diabetes roughly doubled the odds.³ Another study estimated that about half of all BRVO cases could be attributed to hypertension alone, and also identified cardiovascular disease, higher body mass at a young age, and a history of glaucoma as independent risk factors.⁴

The same population study found that visible signs of arterial damage in the retina, specifically arteriovenous nicking and focal narrowing of arterioles, were among the strongest local predictors. Their odds ratios were striking, on the order of 17 and 23 respectively, meaning these eye-specific vascular changes were far more predictive than even diabetes.³ In practical terms, a person with untreated high blood pressure who also has visible signs of arteriolar stiffening in the retina is the textbook candidate for BRVO.

Blood chemistry plays a role too. Elevated homocysteine, an amino acid linked to cardiovascular risk, has been identified as an independent risk factor. One study found that each one-unit increase in plasma homocysteine carried about a 19 percent increase in the odds of BRVO, while folate levels in affected patients tended to be lower than in controls.⁵ A separate study comparing different types of retinal vein occlusion found elevated homocysteine across all types, though the association was even stronger for central retinal vein occlusion than for BRVO.⁶ This does not mean everyone with BRVO needs homocysteine testing, but it may be worth checking in younger patients who lack the usual cardiovascular risk factors.

How BRVO Is Diagnosed

The diagnosis itself is usually straightforward. A dilated eye exam reveals flame-shaped hemorrhages, swollen veins, and sometimes cotton-wool spots along the distribution of the affected vein branch. The pattern is distinctive enough that an experienced clinician can identify it at the slit lamp.

The more important diagnostic question is how much damage the blockage has caused. Optical coherence tomography (OCT) provides a cross-sectional view of the macula and can precisely measure fluid accumulation and swelling. It also reveals structural disruption within the retinal layers, which helps predict visual outcomes. For instance, disruption of the ellipsoid zone, a layer that reflects the health of the photoreceptors, has been linked to worse final vision after treatment.⁷

OCT angiography (OCTA) has become increasingly valuable because it maps the retinal blood vessels without needing a dye injection. It can identify areas where blood flow has dropped out, particularly in the deep capillary layer, which is often the most affected layer in BRVO.⁸ Traditional fluorescein angiography, which involves injecting a dye into a vein in the arm and photographing it as it flows through the retinal vessels, remains useful for assessing the full extent of non-perfused retina, especially when deciding whether laser treatment is needed to prevent abnormal new vessel growth.⁹

Macular Edema and Other Complications

The most common reason BRVO steals vision is macular edema. When blood backs up behind the blockage, pressure rises in the small capillaries, and fluid leaks into the surrounding retinal tissue. The macula, which has the densest concentration of photoreceptors, is exquisitely sensitive to even small amounts of extra fluid. The swelling distorts the layers of the retina and blurs central vision.

The molecular driver of this swelling is vascular endothelial growth factor (VEGF), a protein the retina produces in response to low oxygen. In eyes with BRVO, VEGF levels in the fluid inside the eye are roughly triple those in healthy eyes, and the amount of VEGF correlates directly with the severity of macular edema.¹⁰ Interleukin-6, an inflammatory signaling molecule, is also elevated and tracks alongside VEGF, suggesting that inflammation and leaky vessels feed off each other in a loop.¹¹

A less common but more dangerous complication is retinal neovascularization, the growth of fragile new blood vessels in response to persistent oxygen deprivation. These vessels are poorly constructed and prone to rupture, which can lead to vitreous hemorrhage, a bleed into the gel-filled cavity of the eye that can cause a sudden, severe drop in vision.¹² This complication is more likely in “ischemic” BRVO, where a large area of retina has lost its blood supply entirely.

Treatment With Anti-VEGF Injections

Anti-VEGF drugs injected directly into the eye are now the first-line treatment for macular edema caused by BRVO. A Cochrane systematic review of multiple randomized trials concluded that anti-VEGF agents outperform both laser treatment and steroid injections in terms of visual improvement and reduction of retinal swelling, with a better safety profile than steroids.¹³

In practice, treatment typically starts with monthly injections for the first few months, then tapers. A real-world study following patients over four years found that the average patient needed about four injections in the first six months, then two in the next six, and progressively fewer after that. By the end of four years, only a handful of patients still required treatment. Vision improved by an average of 16 letters on a standard eye chart after the first year.¹⁴ One finding that stood out: patients who began treatment within three months of symptom onset achieved substantially better final vision than those who waited longer, ending up with an average acuity equivalent to roughly 20/25 compared to about 20/80 for late starters.¹⁴

Longer-term data from the RETAIN study found that about half of BRVO patients had complete resolution of macular edema, defined as no fluid for at least six months after the last injection, and that in most cases the last injection was given within two years of starting treatment. Roughly 80 percent achieved a final vision of 20/40 or better regardless of whether edema had fully resolved.¹⁵

Corticosteroids and Laser Photocoagulation

For patients who do not respond well to anti-VEGF therapy, or for whom frequent injections are not feasible, there are alternatives. A dexamethasone intravitreal implant, a slow-release steroid pellet injected into the eye, can reduce swelling and improve vision. A 12-month study of BRVO patients resistant to anti-VEGF treatment showed meaningful reductions in retinal thickness and improvements in visual acuity after switching to the dexamethasone implant.¹⁶ The trade-off is that steroid implants carry a higher risk of raising eye pressure and accelerating cataract formation compared to anti-VEGF drugs.

Laser photocoagulation was the standard treatment before anti-VEGF drugs arrived. Grid laser applied to the swollen macula can still be effective, and scatter laser remains the go-to for preventing or treating neovascularization when abnormal new vessels have formed.¹⁷ In current practice, laser is most often used as an adjunct rather than a standalone treatment. Some patients benefit from a combination approach in which anti-VEGF injections control the acute swelling and laser is added later if needed to address ischemic areas or persistent edema.

Vitrectomy, the surgical removal of the vitreous gel, has also been studied. It can improve both vision and retinal thickness in BRVO patients with persistent macular edema, though adding a procedure called arteriovenous sheathotomy, in which the surgeon separates the artery from the vein at the crossing point, did not clearly improve outcomes over vitrectomy alone in a long-term follow-up study.¹⁸

BRVO as a Signal of Cardiovascular Risk

BRVO does not just affect the eye. Because its root causes overlap so heavily with systemic vascular disease, a diagnosis of BRVO should prompt a broader health check. A large population-based cohort study found that people with BRVO had a significantly higher risk of subsequent stroke, both ischemic and hemorrhagic, compared to matched controls.¹⁹

A case-control study published in the BMJ put it plainly: BRVO should be considered a marker of progressive cardiovascular disease, and the diagnosis should trigger an assessment focused on blood pressure, cholesterol, and blood sugar. General practitioners have a significant role in managing these modifiable risk factors, because treating them can reduce the chance of further vascular events throughout the body, not just in the eye.²⁰ In a sense, the retina acts as a window into overall vascular health, and BRVO is one of the clearer signals that something needs attention.

Major Versus Macular BRVO

Not all BRVO is the same. Clinicians distinguish between “major” BRVO, in which one of the larger branch veins near the optic disc is blocked, and “macular” BRVO, in which a smaller venule within the macula itself is affected. The distinction matters because major BRVO tends to produce more inflammation and a wider area of damage. A study comparing the two found that eyes with major BRVO had significantly higher levels of VEGF, several interleukins, and other inflammatory markers in the fluid inside the eye. Major BRVO was also more likely to show subretinal fluid and structural disorganization of the inner retinal layers on OCT.²¹ Macular BRVO, by contrast, tends to cause a more localized area of swelling and often carries a somewhat better prognosis, though it can still affect central vision significantly if the fovea is involved.

How BRVO Differs From Central Retinal Vein Occlusion

People sometimes confuse BRVO with central retinal vein occlusion (CRVO), but the two conditions have different risk profiles, severity, and outcomes. In CRVO, the main vein draining the entire retina is blocked at or near the optic nerve, producing hemorrhages across the full retina rather than in just one sector. CRVO tends to be more severe and carries a worse visual prognosis on average.

The risk factor profiles also diverge. Research comparing the two found that elevated intraocular pressure was more strongly associated with CRVO, while hypertension and farsightedness were more closely linked to BRVO.²² A third variant, hemiretinal vein occlusion (HRVO), affects one of two trunks of the central vein and falls somewhere between BRVO and CRVO in terms of retinal thickening, fluorescein leakage, and visual acuity at baseline.²³ HRVO is considered an anatomic variant of CRVO rather than a subtype of BRVO, which is worth knowing because the treatment approach and monitoring can differ.

Quality of Life Beyond the Eye Chart

Visual acuity measured on a letter chart does not capture the full impact of BRVO on daily life. Even after successful treatment, patients tend to report lower scores on quality-of-life questionnaires related to near vision and mental health compared to people without eye disease.²⁴ Tasks like reading, using a phone, or threading a needle can remain frustrating if residual distortion or a subtle scotoma persists in the affected part of the visual field. The psychological toll of repeated injections, uncertainty about recurrence, and awareness of underlying cardiovascular risk can also weigh on patients well beyond what an eye chart captures.

Artificial Intelligence in BRVO Screening

Researchers are exploring whether machine-learning models can help identify BRVO early or even predict it before it happens. Deep learning algorithms trained on color fundus photographs have shown the ability to distinguish BRVO from other retinal vascular conditions and from normal eyes, and one model achieved strong performance in segmenting areas of non-perfusion, the oxygen-starved zones that drive complications.²⁵ A separate study went further, using a multimodal deep-learning model to predict BRVO development from fundus images taken before the occlusion actually occurred. Its accuracy was modest but statistically significant, suggesting that subtle vascular changes visible in routine photographs could flag at-risk eyes before a blockage forms.²⁶ These tools are still in the research phase, but they point toward a future in which screening for BRVO risk could be automated as part of standard retinal photography at a routine eye visit.